ASTHMA
ELIGIBILITY & REQUIREMENTS
- Aged 18 years and older.
- Diagnosis of asthma.
- Already on mepolizumab or benralizumab.
WHAT'S INVOLVED
- The trial will run for up to 15 months.
- During this period you will be required to attend up to 18 visits to the Institute for Respiratory Health at QEII Medical Centre in Nedlands.
STUDY OUTLINE
This study is a Phase 3 clinical trial which aims to evaluate a potential new medicine for severe asthma and is not yet approved to treat patients with asthma.
GSK3511294 (also known as the study drug) is a type of medicine called a monoclonal antibody that is made in the laboratory. It works by blocking a specific protein in the body called interleukin-5 which is involved in the severity of asthma and inflammation of the lungs.
The study drug works the same way as three already approved asthma medications: mepolizumab, reslizumab, and benralizumab. These medications are taken every 4 to 8 weeks. However, it is hoped that the effect of the study drug will last over a longer period of time (once every 26 weeks).
To find out if this trial is suitable for you please register below, or contact our Clinical Trials Team at clinicaltrials@resphealth.uwa.edu.au or phone 6151 0888.
PRINCIPAL INVESTIGATOR
Dr John Blakey
LOCATION
Level 2, 6 Verdun Street Nedlands (within the Harry Perkins Institute)
THIS CLINICAL TRIAL IS CURRENTLY CLOSED
Please register your interest for future clinical trials and we will contact you when a suitable trial becomes available.